Saltar al contenido

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray), an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy. ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Verteidigung: EMP-Waffen können USA zerstören

Eine einzige Nuklearexplosion genügt, um die Vereinigten Staaten lahmzulegen – und die Bevölkerung ins Mittelalter zu katapultieren. Das zeigt Steven Starr in seinem neu erschienenen Buch “Nuclear High-Altitude Electromagnetic Pulse”. US gegen EMP-Waffen machtlos Das Stromnetz des Landes würde ebenso zerstört wie das gesamte Kommunikationssystem, die Kühlsysteme der Kernkraftwerke und alle elektronischen Geräte. Der Grund dafür… Verteidigung: EMP-Waffen können USA zerstören

hombre sosteniendo un ordenador portátil con ambas manos

Ciberseguridad de laboratorio: la Casa Blanca recomienda Python

Los laboratorios y las instituciones médicas deberían reconsiderar su estrategia de TI: la Oficina del Director Nacional de Ciberseguridad (ONCD) de la Casa Blanca de EE. UU. publicó ayer lunes un informe que recomienda lenguajes de programación seguros en cuanto a memoria, como Python.

City of Hope scientists destroy leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood published the preclinical findings today. By overcoming challenges, such as drug resistance and treatment relapse common to patients with acute myeloid leukemia (AML), the therapy method could provide a less toxic and more effective approach for older and sicker patients who don’t quality for stem cell transplants — currently the only cure for AML available. Type II interferon (IFNy), a substance produced by immune cells, disrupts the leukemia stem cells’ ability to divide and spread cancer. However, IFNy also stimulates CD38, a protein that suppresses the immune cells’ ability to mount a response against infection. To overcome this challenge, the researchers designed a T cell engager… 

more »City of Hope scientists destroy leukemia stem cells
LabNews de Corax Consultants LLC copyright Corax Consultants LLC

La actividad económica mundial sigue siendo baja

WASHINGTON, 26 de febrero/LabNews. Las perspectivas a medio plazo para el crecimiento económico mundial y la actividad económica siguen siendo escasas. Esto se desprende del último informe del Fondo Monetario Internacional (FMI), publicado antes de la reunión de los ministros de finanzas y gobernadores de bancos centrales del G20 los días 28 y 29 de febrero en Sao Paulo, Brasil. «La economía mundial parece estar en camino de un aterrizaje suave, pero las perspectivas de actividad y crecimiento siguen siendo débiles», señala. «Las perspectivas de crecimiento a medio plazo siguen siendo moderadas, lo que refleja tendencias y desafíos a largo plazo, como el débil crecimiento de la productividad, el envejecimiento de la población, la fragmentación geoecómica y las vulnerabilidades climáticas. Estas tendencias también socavan la convergencia de ingresos y aumentan la vulnerabilidad de las economías a las crisis externas», añadieron los expertos del FMI.

Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “Investors”) for the sale of 10,127,132 of its ordinary shares, for an approximate value of USD 166 million, par value USD 0.01 per share (the “Shares”), at a purchase price of USD 16.41 per Share, or ISK 2,250 per share at foreign exchange rates on February 23, 2024 (the “Transaction”). The Shares are expected to be delivered to the Investors from previously issued treasury shares held by Alvotech’s subsidiary, Alvotech Manco ehf. The Transaction will be made on the Nasdaq Iceland Exchange. Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share